| For: | Huguet JM, Lobo M, Labrador JM, Boix C, Albert C, Ferrer-Barceló L, Durá AB, Suárez P, Iranzo I, Gil-Raga M, Burgos CB, Sempere J. Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases 2019; 7(14): 1732-1752 [PMID: 31417920 DOI: 10.12998/wjcc.v7.i14.1732] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v7/i14/1732.htm |
| Number | Citing Articles |
| 1 |
Sara Boggio, Laura Alaimo, Edoardo Poletto, Alberto Quinzii, Giada Scoccati, Mario De Bellis, Simone Conci, Tommaso Campagnaro, Andrea Ruzzenente. Prognostic Role of Circulating DNA in Biliary Tract Cancers: A Systematic Review and Meta-Analysis. Cancers 2025; 17(21) doi: 10.3390/cancers17213451
|
| 2 |
Alireza Nemati, Mohamad Sadegh Aghajanzadeh, Mahdi Rooberahan. An Overview on Cancer Diagnosis based on Antibody-Based Immune Techniques. Modern Medical Laboratory Journal 2020; 3(2) doi: 10.30699/mmlj17.3.1.100
|
| 3 |
Dina Ioffe, Pooja Phull, Efrat Dotan. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Management and Research 2021; doi: 10.2147/CMAR.S276104
|
| 4 |
Elmira Zolali, Sina Rashedi, Elaheh Dalir Abdolahinia, Nasim Rashedi, Saeideh Allahyari, Nastaran Hashemzadeh. Principles of Biomaterials Encapsulation : Volume Two. 2023; doi: 10.1016/B978-0-12-824345-9.00019-2
|
| 5 |
Kim Saverno, Kristin M Zimmerman Savill, Cherrishe Brown-Bickerstaff, Angele Kotomale, Michael Rodriguez, Bruce Feinberg, Haobo Ren, Mike Blecker, Richard Kim. Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US. The Oncologist 2025; 30(1) doi: 10.1093/oncolo/oyae204
|
| 6 |
Cosmas Rinaldi Adithya Lesmana, Baiq Kirana D. Mandasari. Immunosuppression. 2020; doi: 10.5772/intechopen.94754
|
| 7 |
Hiroki Inada, Hideaki Miyamoto, Satoru Shinriki, Hisanobu Oda, Satoshi Narahara, Motohiro Yoshinari, Katsuya Nagaoka, Daiki Yoshii, Kotaro Fukubayashi, Hiromitsu Hayashi, Hideo Baba, Kisato Nosaka, Yasuhito Tanaka. Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer. International Journal of Clinical Oncology 2024; 29(12) doi: 10.1007/s10147-024-02616-x
|
| 8 |
Chong-You Weng, Cheng-Hung Lee. Adenomyomatosis of distal common bile duct: A case report and systemic review. Medicine 2025; 104(9) doi: 10.1097/MD.0000000000041649
|
| 9 |
Berk Basş, Ömer Küçükdemirci. Initial Biliary Drainage in Unresectable Bismuth Type III Malignant Hilar Obstruction: Comparative Effectiveness of ERCP and PTBD According to Drainage Adequacy in a Retrospective Two-Center Study. Journal of Clinical Medicine 2026; 15(11) doi: 10.3390/jcm15114146
|
| 10 |
Purva Gopal, Marie E. Robert, Xuchen Zhang. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine. Archives of Pathology & Laboratory Medicine 2024; 148(3) doi: 10.5858/arpa.2022-0537-RA
|
| 11 |
Nhu-An Pham, Nikolina Radulovich, Emin Ibrahimov, Sebastiao N. Martins-Filho, Quan Li, Melania Pintilie, Jessica Weiss, Vibha Raghavan, Michael Cabanero, Robert E. Denroche, Julie M. Wilson, Cristiane Metran-Nascente, Ayelet Borgida, Shawn Hutchinson, Anna Dodd, Michael Begora, Dianne Chadwick, Stefano Serra, Jennifer J. Knox, Steven Gallinger, David W. Hedley, Lakshmi Muthuswamy, Ming-Sound Tsao. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-90049-1
|
| 12 |
Milind Javle, Sunyoung Lee, Nilofer S Azad, Mitesh J Borad, Robin Kate Kelley, Smitha Sivaraman, Anna Teschemaker, Ishveen Chopra, Nora Janjan, Shreekant Parasuraman, Tanios S Bekaii-Saab. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. The Oncologist 2022; 27(10) doi: 10.1093/oncolo/oyac150
|
| 13 |
Josep Darbà, Alicia Marsà. Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018). Expert Review of Pharmacoeconomics & Outcomes Research 2021; 21(3) doi: 10.1080/14737167.2021.1842201
|
| 14 |
Yawei Qian, Wenyu Jia, Hongda Liu. Editorial: Biomarkers and immunotherapy of hepatic-biliary-pancreatic cancers. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1301416
|
| 15 |
Ruochen Ying, Anmol Mittal, Kaveh Hajifathalian. Rare Manifestation of Pancreaticobiliary Cancer With Extrahepatic Lesions. Cureus 2023; doi: 10.7759/cureus.43276
|
| 16 |
T.O. Goetze, C. Roderburg, F.W. Friedrich, J. Trojan. New perspectives in biliary tract cancers. ESMO Gastrointestinal Oncology 2024; 5 doi: 10.1016/j.esmogo.2024.100092
|
| 17 |
Ji Hye Jung, So Jeong Yoon, Ok Joo Lee, Sang Hyun Shin, In Woong Han, Jin Seok Heo. Surgical outcomes and prognostic factors of distal common bile duct adenocarcinoma: chronological analysis in a single high-volume institutional experience. BMC Surgery 2022; 22(1) doi: 10.1186/s12893-022-01649-1
|
| 18 |
Filippo de Braud, Juan Valle, Angela Lamarca, David Malka, Antoine Hollebecque. Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine. EMJ Oncology 2022; doi: 10.33590/emjoncol/10184268
|
| 19 |
Gülşah BAYRAM ILIKAN, İlkay AKMANGİT. Percutaneous Transhepatic Cholangiography, Percutaneous Biliary Drainage and Metallic Endoprotesis Applications in Malign Biliary Obstructions. Journal of Contemporary Medicine 2021; 11(1) doi: 10.16899/jcm.764141
|
| 20 |
Jieling Zheng, Shaobo Yao. [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with hepatic cancer. European Journal of Nuclear Medicine and Molecular Imaging 2020; 47(9) doi: 10.1007/s00259-020-04847-2
|
| 21 |
Tanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, Lorenza Rimassa, Junji Furuse, Tatsuya Ioka, Davide Melisi, Teresa Macarulla, John Bridgewater, Harpreet Wasan, Mitesh J Borad, Ghassan K Abou-Alfa, Ping Jiang, Christine F Lihou, Huiling Zhen, Ekaterine Asatiani, Luis Féliz, Arndt Vogel.
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
FGFR2
rearrangements
. Future Oncology 2020; 16(30) doi: 10.2217/fon-2020-0429
|
| 22 |
Ghassan K. Abou-Alfa, Kristen Bibeau, Nikolaus Schultz, Amin Yaqubie, Brittanie Millang, Haobo Ren, Luis Féliz. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma. Targeted Oncology 2022; 17(5) doi: 10.1007/s11523-022-00906-w
|
| 23 |
Narmadha Ramasamy, Pogala Hema Vardhan, Kannan Muthu. Identification of Hub Genes Associated with Bile Duct Cancer Using Integrated Gene Expression Data with Protein-Protein Interaction Network. Journal of Clinical Medicine of Kazakhstan 2026; 23(3) doi: 10.23950/jcmk/18500
|